Evaluation of Protective Immune Responses Induced by DNA Vaccines Encoding EgM123 Protein in Beagle Dogs

Overview

Journal Front Vet Sci

Specialty Veterinary Medicine

Date 2024 Oct 10

PMID 39386253

Authors

Ning Wang

Jinwen Xian

Pengpeng Zhao

Wenqing Zhao

Na Pu

Xinyue Jia

Yanyan Zhang

Xinwen Bo

Zhengrong Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Echinococcus granulosus, known as cystic echinococcosis, is a prominent zoonotic parasitic disease of significant global concern. The definitive hosts serves as the primary reservoir for the transmission of echinococcosis, as well as a main factor in the prevention and control of the disease. Unfortunately, there is currently no commercially available vaccine for these hosts. Nevertheless, DNA vaccines show potential as a feasible strategy for the control and management of parasitic diseases.

Methods: In this study, the EgM123 antigen was selected for its well-documented immunogenic properties to develop a DNA vaccine aimed at combating infection in canines.

Results: The results showed a marked increase in IgG levels in the group vaccinated with pVAX1-EgM123 DNA compared to the PBS group. Additionally, the cytokines IL-1, IFN-, IL-4, and IL-6 were significantly upregulated in the pVAX1-EgM123 DNA vaccine group. Furthermore, in comparison to the PBS control group, the EgM123 DNA vaccine group exhibited a notable 87.85% reduction in worm burden and a 65.00% inhibition in segment development.

Discussion: These findings indicate that the pVAX1-EgM123 DNA vaccine shows promising immunogenicity, successfully eliciting a targeted immune response in canines. Moreover, it significantly diminishes the worm burden and hinders the progression of tapeworms in the pVAX1-EgM123 DNA vaccine group. These findings suggest that the pVAX1-EgM123 DNA vaccine holds promise as a potential candidate vaccine for combating infection in dogs.

References

Prudhomme G, Lawson B, Chang Y, Theofilopoulos A . Immunotherapeutic gene transfer into muscle. Trends Immunol. 2001; 22(3):149-55. DOI: 10.1016/s1471-4906(00)01822-6. View

Zhang W, Zhang Z, Shi B, Li J, You H, Tulson G . Vaccination of dogs against Echinococcus granulosus, the cause of cystic hydatid disease in humans. J Infect Dis. 2006; 194(7):966-74. DOI: 10.1086/506622. View

Zhang F, Ma X, Zhu Y, Wang H, Liu X, Zhu M . Identification, expression and phylogenetic analysis of EgG1Y162 from Echinococcus granulosus. Int J Clin Exp Pathol. 2014; 7(9):5655-64. PMC: 4203177. View

McMahon J, Wells D . Electroporation for gene transfer to skeletal muscles: current status. BioDrugs. 2004; 18(3):155-65. DOI: 10.2165/00063030-200418030-00002. View

Ortona E, Rigano R, Margutti P, Notargiacomo S, Ioppolo S, Vaccari S . Native and recombinant antigens in the immunodiagnosis of human cystic echinococcosis. Parasite Immunol. 2000; 22(11):553-9. DOI: 10.1046/j.1365-3024.2000.00336.x. View

Rashid I, Moire N, Heraut B, Dimier-Poisson I, Mevelec M . Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route. Med Microbiol Immunol. 2016; 206(1):53-62. DOI: 10.1007/s00430-016-0483-9. View

Lorenzo C, Last J, Gonzalez-Sapienza G . The immunogenicity of Echinococcus granulosus antigen 5 is determined by its post-translational modifications. Parasitology. 2005; 131(Pt 5):669-77. DOI: 10.1017/S0031182005008309. View

Li Y, Zhu Y, Sha T, Chen Z, Yu M, Zhang F . A Multi-Epitope Chitosan Nanoparticles Vaccine of Echinococcus granulosus. J Biomed Nanotechnol. 2021; 17(5):910-920. DOI: 10.1166/jbn.2021.3065. View

Vuitton D . The ambiguous role of immunity in echinococcosis: protection of the host or of the parasite?. Acta Trop. 2003; 85(2):119-32. DOI: 10.1016/s0001-706x(02)00230-9. View

10.

PAULUZZI S, De Rosa F, Dottorini S . [Relationship between the antigenic titer and protein content in the hydatid fluid of Echinococcus granulosus]. Ann Sclavo. 1971; 13(4):459-76. View

11.

De Rosa F, Dottorini S, PAULUZZI S . [Vaccination against experimental peritoneal hydatid disease of BALB/C mice with hydatid fluids and their fractions (author's transl)]. Ann Sclavo. 1977; 19(3):470-7. View

12.

Kur J, Holec-Gasior L, Hiszczynska-Sawicka E . Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2009; 8(6):791-808. DOI: 10.1586/erv.09.27. View

13.

Lightowlers M, Liu D, Haralambous A, Rickard M . Subunit composition and specificity of the major cyst fluid antigens of Echinococcus granulosus. Mol Biochem Parasitol. 1989; 37(2):171-82. DOI: 10.1016/0166-6851(89)90149-7. View

14.

Xiao N, Yao J, Ding W, Giraudoux P, Craig P, Ito A . Priorities for research and control of cestode zoonoses in Asia. Infect Dis Poverty. 2013; 2(1):16. PMC: 3750256. DOI: 10.1186/2049-9957-2-16. View

15.

Zhang Z, Li Y, Xie Q, Li P, Nan X, Kong L . The Molecular Characterization and Immunity Identification of Rhoptry Protein 22 of Toxoplasma gondii as a DNA Vaccine Candidate Against Toxoplasmosis. J Eukaryot Microbiol. 2018; 66(1):147-157. DOI: 10.1111/jeu.12639. View

16.

Arce-Fonseca M, Carbajal-Hernandez A, Lozano-Camacho M, Carrillo-Sanchez S, Roldan F, Aranda-Fraustro A . DNA Vaccine Treatment in Dogs Experimentally Infected with . J Immunol Res. 2020; 2020:9794575. PMC: 7222601. DOI: 10.1155/2020/9794575. View

17.

Kutzler M, Weiner D . DNA vaccines: ready for prime time?. Nat Rev Genet. 2008; 9(10):776-88. PMC: 4317294. DOI: 10.1038/nrg2432. View

18.

Zhu Y, He Y, Liu J, Chen J . Adjuvantic cytokine IL-33 improves the protective immunity of cocktailed DNA vaccine of ROP5 and ROP18 against toxoplasma gondii infection in mice. Parasite. 2020; 27:26. PMC: 7174000. DOI: 10.1051/parasite/2020021. View

19.

Petavy A, Hormaeche C, Lahmar S, Ouhelli H, Chabalgoity A, Marchal T . An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis. 2008; 2(1):e125. PMC: 2217674. DOI: 10.1371/journal.pntd.0000125. View

20.

Deplazes P, Rinaldi L, Alvarez Rojas C, Torgerson P, Harandi M, Romig T . Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017; 95:315-493. DOI: 10.1016/bs.apar.2016.11.001. View